No difference was found in tumor PLK4 protein expression among patients with other different clinical characteristics, including age, menopausal status, diabetes, hypertension, histological subtype, myometrial invasion, cervical invasion, cancer antigen (CA) 125 abnormity, CA19-9 abnormity, carcinoembryonic antigen (CEA) abnormity, adjuvant radiotherapy, and adjuvant chemotherapy (all P > 0.050, Table 2). This evidence concerns the gene PLK4 and diabetes mellitus.